Phase II Study of MEDI4736, Tremelimumab, and MEDI4736 in Combination w/ Tremelimumab Squamous Cell Carcinoma of the Head and Neck

NCT02319044 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

267

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck

Interventions

DRUG: MEDI4736
DRUG: Tremelimumab
DRUG: MEDI4736 + Tremelimumab

Sponsor

AstraZeneca

Collaborators

[object Object]